查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2031175

全球雙極性情感障礙及治療市場規模、佔有率、趨勢及成長分析報告（2026-2034年）

Global Bipolar Disorder and Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球雙極性情感障礙及其治療市場規模預計將從2025年的65.2億美元成長至2034年的95.8億美元，2026年至2034年的複合年成長率（CAGR）為4.36%。該市場正經歷穩定成長，主要受精神疾病盛行率上升和人們對雙極性情感障礙認知度提高的推動。雙極性情感障礙是一種慢性疾病，需要透過藥物和心理治療進行長期管理。人們對精神健康的日益關注以及醫療保健服務的擴展，都顯著促進了市場成長。

關鍵促進因素包括公眾健康意識的提高、精神疾病治療的進步以及人們對心理健康服務的日益接受。製藥公司正在研發療效更佳、副作用更小的新藥。遠端醫療和行動醫療應用程式等數位醫療解決方案的引入，正在改善患者獲得治療的途徑。此外，政府為提高公眾心理健康意識提升而採取的措施也促進了市場成長。

由於治療方法和患者照護模式的不斷創新，市場未來前景仍然光明。個人化療法和數位化心理健康解決方案的開發將改善治療效果。新興市場由於醫療服務可近性的提高，蘊藏著巨大的成長機會。隨著全球對心理健康的關注度持續提升，雙極性情感障礙及其治療市場預計將實現永續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業的市場定位、產品系列、策略舉措和財務表現進行了詳細評估。這為深入了解競爭動態和主要參與者所採取的策略提供了寶貴的見解。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球雙極性情感疾患及治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 情緒穩定劑
  • 抗驚厥藥物
  • 抗精神病藥物
  • 抗憂鬱症
  • 抗焦慮藥物
  • 其他藥物類別

第5章：全球雙極性情感疾患及治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 腸外
  • 其他給藥途徑

第6章：全球雙極性情感疾患及治療市場：依作用機轉分類

  • 市場分析、洞察與預測
  • 選擇性血清素再回收抑制劑
  • 血清素-正腎上腺素再回收抑制劑
  • 三環抗憂鬱藥物
  • BETA受體阻斷劑
  • 其他作用機制

第7章 全球雙極性情感障礙及治療市場：按分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球雙極性情感障礙及治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie
    • AstraZeneca
    • Bristol-Myers Squibb
    • Eli Lilly
    • GlaxoSmithKline
    • Janssen Pharmaceuticals
    • Novartis
    • Otsuka Holdings
    • Pfizer
    • Sunovion Pharmaceuticals
    • Teva Pharmaceutical
    • Validus Pharmaceuticals
簡介目錄
Product Code: VMR112115202

The global bipolar disorder and treatment market size is expected to reach USD 9.58 Billion in 2034 from USD 6.52 Billion in 2025, growing at a CAGR of 4.36 during 2026-2034.This market is witnessing steady growth driven by the increasing prevalence of mental health disorders and growing awareness about bipolar disorder. Bipolar disorder is a chronic condition that requires long-term management through medication and therapy. The rising focus on mental health and the expansion of healthcare services are significantly contributing to market growth.

Key drivers include increasing healthcare awareness, advancements in psychiatric treatments, and the growing acceptance of mental health care. Pharmaceutical companies are developing new medications with improved efficacy and reduced side effects. The integration of digital health solutions, such as telemedicine and mobile health applications, is enhancing patient access to treatment. Additionally, government initiatives promoting mental health awareness are supporting market growth.

Future prospects for this market remain promising, with continuous innovation in treatment approaches and patient care models. The development of personalized therapies and digital mental health solutions will enhance treatment outcomes. Emerging markets are expected to offer significant growth opportunities due to improving healthcare access. As the focus on mental health continues to grow globally, the bipolar disorder and treatment market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Class

  • Mood Stabilizers
  • Anticonvulsants
  • Anti-Psychotic Drugs
  • Anti-Depressant Drugs
  • Anti-Anxiety Drugs
  • Other Drug Classes

By Route Of Administration

  • Oral
  • Parenteral
  • Other Routes Of Administration

By Mechanism Of Action

  • Selective Serotonin Reuptake Inhibitors
  • Serotonin Norepinephrine Reuptake Inhibitors
  • Tricyclic Antidepressant Drugs
  • Beta Blockers
  • Other Mechanisms Of Actions

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Otsuka Holdings, Pfizer, Sunovion Pharmaceuticals, Teva Pharmaceutical, Validus Pharmaceuticals.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIPOLAR DISORDER AND TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Mood Stabilizers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Anticonvulsants Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Anti-Psychotic Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Anti-Depressant Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Anti-Anxiety Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIPOLAR DISORDER AND TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Route Of Administration
  • 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Other Routes Of Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIPOLAR DISORDER AND TREATMENT MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Mechanism Of Action
  • 6.2. Selective Serotonin Reuptake Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Serotonin Norepinephrine Reuptake Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Tricyclic Antidepressant Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Beta Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Other Mechanisms Of Actions Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIPOLAR DISORDER AND TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIPOLAR DISORDER AND TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Drug Class
    • 8.2.2 By Route Of Administration
    • 8.2.3 By Mechanism Of Action
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Drug Class
    • 8.3.2 By Route Of Administration
    • 8.3.3 By Mechanism Of Action
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Drug Class
    • 8.4.2 By Route Of Administration
    • 8.4.3 By Mechanism Of Action
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Drug Class
    • 8.5.2 By Route Of Administration
    • 8.5.3 By Mechanism Of Action
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Drug Class
    • 8.6.2 By Route Of Administration
    • 8.6.3 By Mechanism Of Action
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BIPOLAR DISORDER AND TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 AbbVie
    • 10.2.2 AstraZeneca
    • 10.2.3 Bristol-Myers Squibb
    • 10.2.4 Eli Lilly
    • 10.2.5 GlaxoSmithKline
    • 10.2.6 Janssen Pharmaceuticals
    • 10.2.7 Novartis
    • 10.2.8 Otsuka Holdings
    • 10.2.9 Pfizer
    • 10.2.10 Sunovion Pharmaceuticals
    • 10.2.11 Teva Pharmaceutical
    • 10.2.12 Validus Pharmaceuticals